Stock comparison
IDEXX Laboratories
Takeda Pharmaceutical Company Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
TAK
Takeda Pharmaceutical Company Limited
Market cap
$51.34B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | TAK | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 44D | IDXX |
| Benjamin Graham | 80A | 56C | IDXX |
| Philip Fisher | 75B | 40D | IDXX |
| Peter Lynch | 71B | 18F | IDXX |
| Joel Greenblatt | 83C | 32F | IDXX |
| Charlie Munger | 87A | 41D | IDXX |
| Terry Smith | 84A | 36D | IDXX |
Side-by-side metrics
| Metric | IDXX | TAK |
|---|---|---|
| Market cap | $44.12B | $51.34B |
| P/E (TTM) | 39.0x | 43.0x |
| EV/EBIT | 31.6x | 22.0x |
| ROIC (TTM) | 40.66% | 2.59% |
| Gross margin | 62.05% | 58.76% |
| Net margin | 24.63% | 4.26% |
| Revenue CAGR 5y | 7.56% | 7.56% |
| EPS CAGR 5y | 10.79% | -3.46% |
| Debt / Equity | 0.7x | 0.6x |
| Dividend yield | 0.0% | 3.79% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -3.46%+132%
- ROIC (TTM)40.66%vs 2.59%+94%
- Net margin24.63%vs 4.26%+83%
- P/E (TTM)39.0xvs 43.0x+9%
TAK leads on
- Dividend yield3.79%vs 0.0%+100%
- EV/EBIT22.0xvs 31.6x+30%
- Market cap$51.34Bvs $44.12B+14%
- Debt / Equity0.6xvs 0.7x+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.